Raoul C. Coombes

Du Cane Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 141 publications

Author Correction: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Author Correction: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Journal: The EMBO journal

Published: July 06, 2026

Development of a LiDia-SEQ™ platform compatible breast cancer panel and testing with metastatic breast cancer patient samples: A rapid, sample-to-result, fully integrated next-generation sequencing (NGS)-based platform, LiDia-SEQ, for use at the point-of-need.

Development of a LiDia-SEQ™ platform compatible breast cancer panel and testing with metastatic breast cancer patient samples: A rapid, sample-to-result, fully integrated next-generation sequencing (NGS)-based platform, LiDia-SEQ, for use at the point-of-need.

Journal: The journal of liquid biopsy

Published: April 10, 2026

Band-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood.

Band-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood.

Journal: Lab on a chip

Published: April 08, 2026

Expression of Concern: The Transcription Factor FOXO3a is a Crucial Cellular Target of Gefitinib (Iressa) in Breast Cancer Cells.

Expression of Concern: The Transcription Factor FOXO3a is a Crucial Cellular Target of Gefitinib (Iressa) in Breast Cancer Cells.

Journal: Molecular cancer therapeutics

Published: February 05, 2026

Expression of Concern: SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2.

Expression of Concern: SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2.

Journal: Molecular cancer therapeutics

Published: February 05, 2026

Expression of Concern: Gefitinib (Iressa) Represses FOXM1 Expression via FOXO3a in Breast Cancer.

Expression of Concern: Gefitinib (Iressa) Represses FOXM1 Expression via FOXO3a in Breast Cancer.

Journal: Molecular cancer therapeutics

Published: February 05, 2026

Expression of Concern: FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells.

Expression of Concern: FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells.

Journal: Molecular cancer research : MCR

Published: January 16, 2026

Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.

Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.

Journal: Breast cancer research and treatment

Published: July 22, 2025

Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.

Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.

Journal: BMC cancer

Published: July 14, 2025

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Journal: Nature communications

Published: March 06, 2025

Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing.

Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing.

Journal: The Journal of pathology

Published: February 10, 2025

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Journal: The EMBO journal

Published: December 17, 2024

Showing 1-12 of 141

Last Updated: 09/26/2026